Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2008
11/13/2008WO2008137159A1 Human anti-vegf polyclonal antibodies and uses thereof
11/13/2008WO2008136867A2 Chlamydia pneumoniae vaccine and methods for administering such a vaccine
11/13/2008WO2008136848A2 Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
11/13/2008WO2008136774A1 Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
11/13/2008WO2008136736A2 Immunoregulatory structures from normally occurring proteins
11/13/2008WO2008135514A1 Vaccine
11/13/2008WO2008135446A2 Klebsiella antigens
11/13/2008WO2008135419A2 Anti-il-6-agents for improving primary functioning of allogenic grafts
11/13/2008WO2008135380A1 Method for stabilizing a protein
11/13/2008WO2008135237A1 Complement factor h-derived short consensus repeat-antibody constructs
11/13/2008WO2008135067A1 Method for the diagnosis of tuberculosis
11/13/2008WO2008134935A1 Truncated human papillomavirus type 18 l1 proteins
11/13/2008WO2008134934A1 A truncated l1 protein of human papillomavirus 16
11/13/2008WO2008134879A1 Il-12 immunotherapy for cancer
11/13/2008WO2008134878A1 Compositions and methods for cancer treatment
11/13/2008WO2008134876A1 Cancerous disease modifying antibodies
11/13/2008WO2008134830A1 Method to obtain monophosphoryl lipid a from bordetella pertussis as a by-product of the cellular pertussis vaccine production
11/13/2008WO2008115641A3 Modular nanoparticles for adaptable vaccines
11/13/2008WO2008112192A3 Epha3 antibodies for the treatment of solid tumors
11/13/2008WO2008104183A3 Recombinant anti-epidermal growth factor receptor antibody compositions
11/13/2008WO2008085562A3 Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
11/13/2008WO2008085557A3 Alphavirus replicon particles encoding il- 12 as immunological adjuvants
11/13/2008WO2008082889A3 Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
11/13/2008WO2008081331A3 Enhancing the level of antibody expression by framework re-engineering
11/13/2008WO2008076915A3 Treatment of pigs with pcv2 antigen
11/13/2008WO2008073615A3 N-glycosylation mutant of melanoma differentiation associated gene-7
11/13/2008WO2008068631A3 Vaccines including antigen from four strains of influenza virus
11/13/2008WO2008066631A3 Methods of disrupting quorum sensing to affect microbial population cell density
11/13/2008WO2008061013A3 Antibody-based diagnostics and therapeutics
11/13/2008WO2008052173A3 Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
11/13/2008WO2008052111A3 Resistin antagonists and their use
11/13/2008WO2008045437A9 Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
11/13/2008WO2008042611A3 Method of using il6 antagonists with mitoxantrone for prostate cancer
11/13/2008WO2008042024A3 Neuroactive fragments of app
11/13/2008WO2008039983A3 Methods and compositions using mutant gp120
11/13/2008WO2008035210A3 Recombinant hbsag virus-like particles containing polyepitopes of interest, their production and use
11/13/2008WO2008030543A3 Tyrosine, serine and threonine phosphorylation sites
11/13/2008WO2008030538A3 Cancer stem cell-targeted cancer therapy
11/13/2008WO2008024413A3 Tissue culture system for production of hepatitis c virus
11/13/2008WO2008022349A3 Agents for blood-brain barrier delivery
11/13/2008WO2008022146A3 Polymer-surfactant nanoparticles for sustained release of compounds
11/13/2008WO2008021976A3 Anti-interferon alpha monoclonal antibodies and methods for use
11/13/2008WO2008006036A3 Conditioned cell immunization
11/13/2008WO2007146957A3 Ror1 as a therapeutic target for lung cancer
11/13/2008WO2007143606A3 Hiv-1 clade a consensus sequences, antigens, and transgenes
11/13/2008WO2007133835A3 Ras mutation and compositions and methods related thereto
11/13/2008WO2007126958A3 Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites
11/13/2008WO2007126885A3 Live, attenuated pneumococcal vaccine
11/13/2008WO2007125089A3 Antibodies for the detection of bacillus anthracis and vaccine against b. anthracis infections
11/13/2008US20080282363 Methods for producing human antibodies in scid mice
11/13/2008US20080281083 Integrin binding protein p80 for use as evaluative tool in tumor diagnostics
11/13/2008US20080280822 Nucleic acid and corresponding protein entitled 161P5C5 useful in treatment and detection of cancer
11/13/2008US20080280368 Parasitic helminth cuticlin proteins and uses thereof
11/13/2008US20080280354 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
11/13/2008US20080280327 Expression vector comprising nucleotide sequences coding bone morphogenic protein/selectin fusion for use in treatment and prvention of inflammatory diseases
11/13/2008US20080280322 Transgenic cell for use as bioreactor in production of human estrogen receptor (HER) specific monoclonal antibody for use in targeted destruction of tumor cells
11/13/2008US20080280320 Formulation of antigen
11/13/2008US20080280281 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
11/13/2008US20080279955 Pharmaceutical microparticles
11/13/2008US20080279950 Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof
11/13/2008US20080279946 Methods and compositions for increasing infrared absorptivity of a target
11/13/2008US20080279926 Vaccine Compositions Comprising a Saponin Adjuvant
11/13/2008US20080279924 HLA class I A2 tumor associated antigen peptides and vaccine compositions
11/13/2008US20080279897 Method of Treating Cellular Damage
11/13/2008US20080279896 Pretreatment, concurent, aftertreatment muscle stimulating therapy; deactivation of nervous system
11/13/2008US20080279895 Therapy or prevention of headaches; administering neurotoxin by injection
11/13/2008US20080279894 Stimulating immunology response; vaccine efficiency; therapy for infections, drug resistant tumors; anticancer agents; autoimmune disease; antiallergens; activation natural killer cells using complex of glycolipid and CD-1 antigen presenting cell
11/13/2008US20080279893 Lawsonia intracellularis immunological proteins
11/13/2008US20080279892 Attenuation of respiratory syncytial virus by mutagenisi of M2-1 gene; immunogenic composition
11/13/2008US20080279891 Viral Adjuvants
11/13/2008US20080279890 Viral antigens
11/13/2008US20080279889 Administering porcine circovirus type 2 antigen; antiulcer gents; nephritis, sexual and urogenital disorders
11/13/2008US20080279888 Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
11/13/2008US20080279887 Recombinant virus encoding an antigen of a disease state; second recombinant virus encoding an immunostimulatory molecule with an exogenous immunostimulatory molecule, chemotherapeutic drug, antibiotic, antiviral drug or antifungal drug.
11/13/2008US20080279886 recombinant virus that substantially lacks a phosphoprotein gene that is not required for growth of the virus in cultured cells but is important for establishing a latent infection
11/13/2008US20080279881 Modified obligate parasite polypeptide for use in treatment and prevention of scrub typhus infection
11/13/2008US20080279880 Peptide vaccines against group a streptococci
11/13/2008US20080279879 Therapeutic mixture for boosting cross-clade human immunodeficiency viral envelope protein specific immunoglobulin; immunotherapy
11/13/2008US20080279878 Compositions of Hsp60 Peptides and Viral Antigens for Vaccination and Diagnosis
11/13/2008US20080279877 Human papilloma viral (HPV) thermostable fusion for use in developing vaccine for infection prevention; cervical cancer treatment
11/13/2008US20080279876 Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
11/13/2008US20080279875 Administering a recombinantly produced protein encoded by one of the open reading frames in the porcine circovirus type 2 antigen genome
11/13/2008US20080279874 Compositions and methods for modulation of plk1 kinase activity
11/13/2008US20080279873 Active immunization to generate antibodies to soluble a-beta
11/13/2008US20080279872 Using dendritic cells expressing chymotrypsin protein fragment as immunostimulatory tool for targeting cancer cells associated with ovarian tissue
11/13/2008US20080279871 Immunogenic composition
11/13/2008US20080279870 ALK protein tyrosine kinase, cells and methods embodying and using same
11/13/2008US20080279869 Method for reducing neuronal degeneration by administering cns-derived peptides or activated t cells
11/13/2008US20080279868 Antibody-Drug Conjugates and Methods of Use
11/13/2008US20080279867 Prevent trabsplant rejection; autoimmune diseases
11/13/2008US20080279866 Treating lymphomas, allergies and autoimmune diseases via apoptotic induction; using ATP-competitive inhibitor, 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one (KU-55933) and lymphocyte specific immunoglobulins
11/13/2008US20080279865 Using cytotoxic t-lymphocyte antigen-4 specific immunoglobulin and anti-androgens as therapeutic tools in treatment of cell proliferative disorders
11/13/2008US20080279864 High Throughput Screen Utilizing Newly Discovered Intramolecular Neuronal Calcium Channel Interactions To Discover New Analgesics
11/13/2008US20080279863 Using polyclonal goose antibodies as therapeutic tool in preventing viral infection of birds and mammals
11/13/2008US20080279862 Using interleukin-1 specfic immunoglobulin fusion and tumor necrosis factor inhibitors to treat inflammatory and/or autoimmune disorders
11/13/2008US20080279861 Method for stimulating a host immune system by administering an allogeneic cell material
11/13/2008US20080279860 Using endothelial growth factor specific monoclonal antibody for treatment and prevention of metastatic ovarian cancer; immunotherapy
11/13/2008US20080279859 Neurite outgrowth inhibitor -66 receptor (NOGO-66) specific monoclonal antibody for treatment and prevention of nervous system, muscular, tumor and vision disorders
11/13/2008US20080279858 Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
11/13/2008US20080279857 Therapeutic Agent
1 ... 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 ... 1823